Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cellectar Biosciences, Inc. (CLRB)

Cellectar Q2 net loss $6.9 million; Phase 3 iopofosine site activation begins

Negative Impact 3 of 5 earnings Written later

Cellectar Biosciences reported a second-quarter 2026 net loss of $6.9 million, or $0.57 per share, up from $5.4 million in the year-earlier quarter, as research and development spending rose on new trials. The company said it started site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia and plans a New Drug Application in mid-2027, and it reported cash of $34.0 million, which it says funds operations into the second quarter of 2027.

Key points

  • Net loss of $6.9 million, or $0.57 per share, for the quarter ended June 30, 2026, versus $5.4 million, or $3.39 per share, a year earlier.
  • Cash and cash equivalents of $34.0 million at June 30, 2026, up from $13.2 million at December 31, 2025, including net proceeds of about $31.7 million from the May 2026 offering.
  • R&D expenses rose to about $4.6 million from $2.4 million; G&A expenses fell to about $2.6 million from $3.6 million.
  • Site activation started for the Phase 3 confirmatory study; the New Drug Application is planned for mid-2027.

The filing

CompanyCellectar Biosciences, Inc. (CLRB)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:25 AM ET
Accession number0001104659-26-095460

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.